2011 Update: antigen-specific therapy in type 1 diabetes.

ABSTRACT:

Purpose of review

To update on the clinical trials using antigen-specific therapies in autoimmune diabetes.

Recent findings

Type 1 diabetes is now a predictable disease with the measurement of islet autoantibodies, and the incidence is increasing dramatically. Well tolerated and effective interventions are needed to stop the underlying autoimmune destruction of insulin-producing beta cells. Beta-cell antigens, insulin and glutamic acid decarboxylase, are being used to preserve endogenous insulin production in individuals with new-onset diabetes and to prevent diabetes. The results of antigen-specific immune intervention trials are reviewed and consideration is given to future directions for inducing tolerance in type 1 diabetes.

Summary

Antigen-specific immune therapi

SUBMITTER: Michels AW 

PROVIDER: S-EPMC4016762 | biostudies-literature | 2011 Aug

REPOSITORIES: biostudies-literature